|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
immunotherapy
|
|
gptkbp:administeredBy
|
gptkb:nivolumab
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2011
|
|
gptkbp:ATCCode
|
L01XC11
|
|
gptkbp:blackBoxWarning
|
immune-mediated adverse reactions
|
|
gptkbp:brand
|
gptkb:Yervoy
|
|
gptkbp:CASNumber
|
477202-00-9
|
|
gptkbp:combinationTherapy
|
yes
|
|
gptkbp:contraindication
|
severe hypersensitivity
|
|
gptkbp:developedBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:discoveredBy
|
gptkb:James_Allison
|
|
gptkbp:form
|
solution for infusion
|
|
gptkbp:halfLife
|
~15 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ipilimumab
|
|
gptkbp:immunogenicity
|
low
|
|
gptkbp:indication
|
gptkb:advanced_melanoma
metastatic melanoma
adjuvant therapy
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
CTLA-4 inhibitor
|
|
gptkbp:molecularWeight
|
~148 kDa
|
|
gptkbp:monitors
|
liver function
endocrine function
|
|
gptkbp:monotherapy
|
yes
|
|
gptkbp:origin
|
fully human antibody
|
|
gptkbp:patentExpired
|
no (as of 2024)
|
|
gptkbp:pharmacokinetics
|
linear
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
pruritus
hepatitis
rash
inflammatory bowel disease
hypophysitis
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:target
|
gptkb:CTLA-4
|
|
gptkbp:type
|
IgG1 kappa antibody
|
|
gptkbp:UNII
|
83HN0GTJ6D
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
colorectal cancer
melanoma
hepatocellular carcinoma
renal cell carcinoma
malignant pleural mesothelioma
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|